» Articles » PMID: 36073731

The Australia Smoking and Vaping Model: The Potential Impact of Increasing Access to Nicotine Vaping Products

Overview
Specialty Public Health
Date 2022 Sep 8
PMID 36073731
Authors
Affiliations
Soon will be listed here.
Abstract

Background: We model the potential impact of relaxing current nicotine vaping product (NVP) restrictions on public health in Australia.

Aims And Methods: A Restricted NVP Scenario was first developed to project current smoking and vaping rates, where a U.S. smoking model was calibrated to recent Australian trends. To model less restrictive NVP policies, a Permissive NVP Scenario applied rates of switching from smoking to vaping, initiation into NVP and cigarette use, and cessation from smoking and vaping based on U.S. trends. The model measures vaping risk relative to the excess mortality rate of smoking. The public health impacts are measured as the difference between smoking- and vaping-attributable deaths (SVADs) and life years lost (LYLs) in the Restricted and Permissive NVP Scenarios. Sensitivity analysis is conducted regarding the NVP excess risk and other factors.

Results: Assuming an NVP excess risk of 5% that of smoking, 104.2 thousand SVADs (7.7% reduction) and 2.05 million LYLs (17.3% reduction) are averted during 2017-2080 in the Permissive NVP Scenario compared to the Restricted NVP Scenario. Assuming 40% NVP excess risk, 70 thousand SVADs and 1.2 million LYLs are averted. The impact is sensitive to the rate at which smokers switch to NVPs and quit smoking, and relatively insensitive to the smoking initiation and NVP initiation and cessation rates.

Conclusions: The model suggests the potential for public health gains to be achieved by relaxing NVP access regulations. However, the model would benefit from better information regarding the impact of NVPs on smoking under a relaxation of current restrictions.

Implications: Australia has implemented a strong array of cigarette-oriented policies, but has restricted access to NVPs. The Smoking and Vaping Model offers a framework for modeling hypothetical policy scenarios. The Australian model shows the potential for public health gains by maintaining cigarette-oriented policies while relaxing the current restrictive NVP policy. Modeling results under a permissive NVP policy are particularly sensitive to the estimated rates of smoking cessation and switching to vaping, which are not well established and will likely depend on past and future cigarette-oriented policies and the specific NVP policies implemented in Australia.

Citing Articles

Trends in the global, regional, and national burden of bladder cancer from 1990 to 2021: an observational study from the global burden of disease study 2021.

Su X, Tao Y, Chen F, Han X, Xue L Sci Rep. 2025; 15(1):7655.

PMID: 40038504 PMC: 11880295. DOI: 10.1038/s41598-025-92033-5.


Pharmacists' Perspectives on Nicotine Vaping Products (NVPs) for Smoking Cessation in Australia: A Qualitative Analysis.

Le D, Saba M, Bhurawala H, Rahman M, Shah S, Saini B Pharmacy (Basel). 2025; 13(1).

PMID: 39998009 PMC: 11858986. DOI: 10.3390/pharmacy13010011.


Association between electronic cigarette use and respiratory outcomes among people with no established smoking history: a comprehensive review and critical appraisal.

Selya A, La Rosa G, Spicuzza L, Morjaria J, Caci G, Polosa R Intern Emerg Med. 2025; .

PMID: 39992483 DOI: 10.1007/s11739-025-03894-7.


Global burden of bladder cancer attributable to smoking in 204 countries and territories, 1990-2019.

Yuan J, Chen L, Zhou J, Zang X, Zhang T, Ju X Heliyon. 2024; 10(13):e34114.

PMID: 39091950 PMC: 11292503. DOI: 10.1016/j.heliyon.2024.e34114.


The potential impact of removing a ban on electronic nicotine delivery systems using the Mexico smoking and vaping model (SAVM).

Sanchez-Romero L, Li Y, Zavala-Arciniega L, Gallegos-Carrillo K, Thrasher J, Meza R medRxiv. 2024; .

PMID: 38746147 PMC: 11092684. DOI: 10.1101/2024.04.28.24306511.


References
1.
Bachand A, Sulsky S, Curtin G . Assessing the Likelihood and Magnitude of a Population Health Benefit Following the Market Introduction of a Modified-Risk Tobacco Product: Enhancements to the Dynamic Population Modeler, DPM(+1). Risk Anal. 2017; 38(1):151-162. DOI: 10.1111/risa.12819. View

2.
Robertson L, Hoek J, Blank M, Richards R, Ling P, Popova L . Dual use of electronic nicotine delivery systems (ENDS) and smoked tobacco: a qualitative analysis. Tob Control. 2018; 28(1):13-19. PMC: 6317506. DOI: 10.1136/tobaccocontrol-2017-054070. View

3.
Gottlieb S, Zeller M . A Nicotine-Focused Framework for Public Health. N Engl J Med. 2017; 377(12):1111-1114. DOI: 10.1056/NEJMp1707409. View

4.
Borland R, Murray K, Gravely S, Fong G, Thompson M, McNeill A . A new classification system for describing concurrent use of nicotine vaping products alongside cigarettes (so-called 'dual use'): findings from the ITC-4 Country Smoking and Vaping wave 1 Survey. Addiction. 2019; 114 Suppl 1:24-34. PMC: 6669110. DOI: 10.1111/add.14570. View

5.
Levy D, Cummings K, Villanti A, Niaura R, Abrams D, Fong G . A framework for evaluating the public health impact of e-cigarettes and other vaporized nicotine products. Addiction. 2016; 112(1):8-17. PMC: 5079857. DOI: 10.1111/add.13394. View